Maria Fernanda Mojica, MSC, PhD
Senior instructor, Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine
About my role in the ARLG
I received an Early Stage Investigator Seed Grant to define the mechanisms of resistance to a novel carbapenem, by providing fundamental biochemical and microbiological information about the interaction of this carbapenem with relevant β-lactamases.
As a microbiologist who has worked with infectious disease specialists, I am fully aware of the critical role of β-lactamases as the main drivers of β-lactam resistance. Eager to know more about these fascinating enzymes, I earned a PhD in Biochemistry studying β-lactamases, specifically Metallo- β-lactamases (MBLs), to understand how they work with the end goal of designing inhibitors.
I applied for the Early Stage Investigator Grant from ARLG in the third year of my postdoc training. Receiving it bolstered my confidence and reinforced my desire to continue on the academic path. It has been a terrific learning experience on all fronts. Being the PI of a grant trained me in the administrative duties you are seldom aware of when you are not in that position. This award also helped me transition to a faculty position.
About my research
Antimicrobial resistance (AMR) is a major public health threat that requires coordinated efforts to counteract its spread and development. These efforts include antimicrobial stewardship, developing novel agents, and global surveillance of resistance mechanisms.
In line with these efforts and the ARLG’s scientific agenda and mission, this project evaluates a novel carbapenem, against the most common β-lactamases in the United States. It also assesses the efficacy of this agent, combined with different β-lactamase inhibitors, as potential treatments for infections caused by multidrug-resistant Gram-negative bacilli.
Why is this research important?
β-lactams are the cornerstone of antibiotic therapy, and β-lactamases are the main resistance mechanisms to these antibiotics. Antimicrobial resistance is a natural process; hence, the emergence of β-lactamases with improved characteristics that confer better chances of survival to the bacteria is expected.
In this scenario, the development of β-lactamase inhibitors has been instrumental in preserving the efficacy of otherwise obsolete molecules. By studying the mechanism by which these enzymes interact with β-lactams, we can design sturdier β-lactams and, importantly, more efficient inhibitors.
Impact of the ARLG mentoring and funding on my career
My ARLG mentor has given me invaluable advice on how to start a career in academia, build my own lab, and expand my research interests to find my niche. In addition to science, my mentor has taught me that the key to success is to balance work and personal life. Given the hectic rhythm of modern life, I treasure this lesson.
ARLG is a network you can be part of regardless of your scientific background. I would like to encourage PhD trainees in microbiology, biochemistry, chemistry, bioinformatics, and similar fields to apply for funding opportunities through the ARLG. Meeting the challenge to combat AMR demands a multidisciplinary approach. Networks like the ARLG help to provide that solution.